Tackling Poor Bioavailability with Early Formulation Strategies
De-risking oral clinical development with UpperSolv™.
High clinical failure rates are often linked to poor ADME properties. This guide introduces the UpperSolv™ platform, a science-driven solution for oral formulations with improved bioavailability.
High clinical failure rates are often linked to poor ADME properties. This guide introduces the UpperSolv™ platform, a science-driven solution for oral formulations with improved bioavailability.
Why Bioavailability Matters
Poor absorption is a leading cause of clinical attrition, so addressing it early protects both budget and timeline.
The UpperSolv™ Platform
A structured screening approach identifies the most suitable enabling formulation for each molecule.
De-Risking Clinical Development
Early formulation data supports better first-in-human decisions and smoother progression to later phases.
Download This White Paper
Biotechnology Media Insights
Continue to Biotechnology Media Insights to access this white paper.